Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00740714 · ClinicalTrials.gov registry record · Phase 3
Effects of Coenzyme Q10 (CoQ) in Parkinson Disease
A Phase 3 study, sponsored by Weill Medical College of Cornell University.
- Terminated
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT00740714: Clinical Trial Phase 3 study, sponsored by Weill Medical College of Cornell University.
NCT00740714 is a Phase 3 study that was terminated before completion, run by Weill Medical College of Cornell University. The registered enrollment target is 600 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00740714, a Phase 3 study, was terminated before completion, sponsored by Weill Medical College of Cornell University.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of high dosages of Coenzyme Q10 in slowing clinical decline in people who have early Parkinson disease.
Primary Outcome
Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 16 or the time of sufficient disability to require dopaminergic therapy or study closure, whichever occurs first. The UPDRS score has three components, each consisting of questions answered on a 0-4 point scale. Part I assesses mentation, behavior and mood; Part II assesses activities of daily living in the week prior to the designated visit; and Part III assesses motor abi
Interventions
- DRUG Coenzyme Q10 with vitamin E
- DRUG placebo with vitamin E
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-08 |
| Phase | Phase 3 |
Why NCT00740714 stopped before completion
NCT00740714 is an interventional study that assigns participants to a tested intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (22% lower).
The record links to 0 conditions, and to 2 interventions - of which Coenzyme Q10 with vitamin E is the first listed.
NCT00740714 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00740714 about?
NCT00740714 is a clinical study titled "Effects of Coenzyme Q10 (CoQ) in Parkinson Disease". The purpose of this study is to evaluate the safety and effectiveness of high dosages of Coenzyme Q10 in slowing clinical decline in people who have early Parkinson disease.
What is the current status of trial NCT00740714?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2008-12. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00740714?
The interventions under investigation include: Coenzyme Q10 with vitamin E (DRUG), placebo with vitamin E (DRUG).
Who is sponsoring clinical trial NCT00740714?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00740714's enrollment target sits among peer trials
600 608th of 2000 higher than 1,363 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia